Top Abstract Purchase Related
Home
>
Node
>
Subnode

Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand

Thapinta, D.; Jenkins, R.A.; Morgan, P.A.; Chiu, J.; Boenim, W.; Bussaratid, V.; Chaddic, C.; Naksrisook, S.; Phonrat, B.; Sirijongdee, N.; Sornsathapornkul, P.; Sontirat, A.; Srisaengchai, P.; Suwanarach, C.; Wongkamhaeng, S.; Brown, A.E.; Khamboonruang, C.; Nitayaphan, S.; Pitisuttithum, P.; Thongchareon, P.

Journal of Acquired Immune Deficiency Syndromes 30(5): 503-513

2002

ISSN/ISBN: 1525-4135
PMID: 12154341
DOI: 10.1097/00126334-200208150-00006
Document Number: 242654
The factors believed to be predictive of retention through the recruitment and screening processes for preventive HIV trials were investigated in a large multisite phase I/II HIV vaccine trial in Thailand . A total of 806 volunteers were included in the study. Retention through recruitment was equal to or greater than in previous smaller trials with similar populations. The data suggested that recruitment proceeded in a stepwise manner with different influences at each step. Demographic and motivational variables were most important in predicting retention in making and keeping screening appointments. Altruistic or mixed altruistic and nonaltruistic motives were associated with greater retention. Laboratory/medical variables appeared to be the main influence on retention during screening, although some volunteers withdrew for different reasons. The frequent presence of mixed (altruistic and nonaltruistic) motives at initial contact suggests that motivation for trials is more complex than has been previously acknowledged.

Document emailed within 0-6 h
Secure & encrypted payments

Rerks-Ngarm, S.; Premsri, N.; Namwat, C.; Khamboonruang, C.; Kunasol, P.; Pitisuttithum, P.; Kaewkungwal, J.; Nitayaphan, S.; Eamsila, C.; Benenson, M.W.; Paris, R.; Kim, J.H.; Rerks-Ngarm, S.; Chunsuttiwat, S.; Premsri, N.; Namwat, C.; Kunasol, P.; Thongcharoen, P.; Khamboonruang, C.; Pitisuttithum, P.; Bussaratid, V.; Maek-a-nantawat, W.; Dhitavat, J.; Suntharasamai, P.; Pungpak, S.; Vanijanonta, S.; Kaewkungwal, J.; Khamsiriwatchara, A.; Jarujareet, P.; Nitayaphan, S.; Easmila, C.; Tabprasit, S.; Paris, R.; Benenson, M.; Morgan, P. 2011: Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148) Vaccine 29(25): 4285-4292
Jenkins, R.A.; Thapinta, D.; Morgan, P.A.; Wongkamhaeng, S.; Sornsathapornkul, P.; Bussaratid, V.; Sontirat, A.; Pitisuttithum, P.; Thongchareoen, P.; Khamboonruang, C.; Suriyanon, V.; Nitayaphan, S.; Brown, A.E. 2005: Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand Journal of Acquired Immune Deficiency Syndromes 40(5): 592-599
Bakari, M.; Munseri, P.; Francis, J.; Aris, E.; Moshiro, C.; Siyame, D.; Janabi, M.; Ngatoluwa, M.; Aboud, S.; Lyamuya, E.; Sandström, E.; Mhalu, F. 2013: Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/Ii HIVIS 03 trial Bmc Public Health 13: 1149
Vaccari, M.; Poonam, P.; Franchini, G. 2010: Phase IIi HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV Expert Review of Vaccines 9(9): 997-1005
Tarimo, E.A.M.; Thorson, A.; Kohi, T.W.; Bakari, M.; Sandstrom, E.; Mhalu, F.; Kulane, A. 2011: A qualitative evaluation of volunteers' experiences in a phase I/Ii HIV vaccine trial in Tanzania Bmc Infectious Diseases 11: 283
Tarimo, E.A.M.; Thorson, A.; Kohi, T.W.; Bakari, M.; Mhalu, F.; Kulane, A. 2011: Reasons for declining to enroll in a phase i and Ii HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania Plos one 6(2): E14619
Pérez-Losada, M.; Jobes, D.V.; Sinangil, F.; Crandall, K.A.; Arenas, M.; Posada, D.; Berman, P.W. 2011: Phylodynamics of HIV-1 from a phase IIi AIDS vaccine trial in Bangkok, Thailand PLOS one 6(3): E16902
Tarimo, E.A.M.; Munseri, P.; Aboud, S.; Bakari, M.; Mhalu, F.; Sandstrom, E. 2014: Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/Ii HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania Plos one 9(3): E90938
Kibuuka, H.; Guwatudde, D.; Kimutai, R.; Maganga, L.; Maboko, L.; Watyema, C.; Sawe, F.; Shaffer, D.; Matsiko, D.; Millard, M.; Michael, N.; Wabwire-Mangen, F.; Robb, M. 2009: Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa Plos one 4(4): E5164
Pitisuttithum, P.; Choopanya, K.; Bussaratid, V.; Vanichseni, S.; van Griensven, F.; Phonrat, B.; Martin, M.; Vimutsunthorn, E.; Sangkum, U.; Kitayaporn, D.; Tappero, J.W.; Heyward, W.; Francis, D. 2007: Social harms in injecting drug users participating in the first phase IIi HIV vaccine trial in Thailand Journal of the Medical Association of Thailand 90(11): 2442-2448
Andrasik, M.P.; Sesay, F.Albertina.; Isaacs, A.; Oseso, L.; Allen, M. 2020: Social Impacts among Participants in HIV Vaccine Trial Network (HVTN) preventive HIV vaccine trials Journal of Acquired Immune Deficiency Syndromes 2020
Nosten, F.; Luxemburger, C.; Kyle, D.E.; Ballou, W.R.; Wittes, J.; Wah, E.; Chongsuphajaisiddhi, T.; Gordon, D.M.; White, N.J.; Sadoff, J.C.; Heppner, D.G. 1996: Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group Lancet 348(9029): 701-707
Ramanathan, V.D.; Kumar, M.; Mahalingam, J.; Sathyamoorthy, P.; Narayanan, P.R.; Solomon, S.; Panicali, D.; Chakrabarty, S.; Cox, J.; Sayeed, E.; Ackland, J.; Verlinde, C.; Vooijs, D.; Loughran, K.; Barin, B.; Lombardo, A.; Gilmour, J.; Stevens, G.; Smith, M.S.; Tarragona-Fiol, T.; Hayes, P.; Kochhar, S.; Excler, J.-L.; Fast, P. 2009: A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers Aids Research and Human Retroviruses 25(11): 1107-1116
Allen, M.; Lau, C-Yen. 2008: Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention Social Science and Medicine 66(4): 945-951
Agnandji, S.Todagbe.; Lell, B.; Soulanoudjingar, S.Solmeheim.; Fernandes, Jé.Francisco.; Abossolo, Béatrice.Peggy.; Conzelmann, C.; Methogo, B.Gaelle.Nfono.Ondo.; Doucka, Y.; Flamen, A.; Mordmüller, B.; Issifou, S.; Kremsner, P.Gottfried.; Sacarlal, J.; Aide, P.; Lanaspa, M.; Aponte, J.J.; Nhamuave, A.; Quelhas, D.; Bassat, Q.; Mandjate, S.; Macete, Eébio.; Alonso, P.; Abdulla, S.; Salim, N.; Juma, O.; Shomari, M.; Shubis, K.; Machera, F.; Hamad, A.Said.; Minja, R.; Mtoro, A.; Sykes, A.; Ahmed, S.; Urassa, A.Martin.; Ali, A.Mohammed.; Mwangoka, G.; Tanner, M.; Tinto, H 2011: First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children New England Journal of Medicine 365(20): 1863-1875
Newman, P.A.; Roungprakhon, S.; Tepjan, S.; Yim, S. 2010: Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand Vaccine 28(4): 958-964
Jones, W.R.; Bradley, J.; Judd, S.J.; Denholm, E.H.; Ing, R.M.; Mueller, U.W.; Powell, J.; Griffin, P.D.; Stevens, V.C. 1988: Phase i clinical trial of a World Health Organisation birth control vaccine Lancet 1(8598): 1295-1298
Vanichseni, S.; Tappero, J.W.; Pitisuttithum, P.; Kitayaporn, D.; Mastro, T.D.; Vimutisunthorn, E.; van Griensvan, F.; Heyward, W.L.; Francis, D.P.; Choopanya, K. 2004: Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand Aids 18(2): 311-316
Giocos, G.; Kagee, A.; Swartz, L. 2008: Predicting hypothetical willingness to participate (WTP) in a future phase IIi HIV vaccine trial among high-risk adolescents Aids and Behavior 12(6): 842-851
Stoute, Jé.A.; Heppner, D.Gray.; Mason, C.J.; Siangla, J.; Opollo, M.O.; Kester, K.E.; Vigneron, L.; Voss, G.; Walter, M.J.; Tornieporth, N.; Cohen, J.D.; Ballou, W.Ripley. 2006: Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya American Journal of Tropical Medicine and Hygiene 75(1): 166-170